- Home
- DEVS vs APLM Comparison
DEVS vs APLM Comparison
Compare DEVS & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEVS
- APLM
- Stock Information
- Founded
- DEVS N/A
- APLM 2016
- Country
- DEVS Canada
- APLM United States
- Employees
- DEVS N/A
- APLM N/A
- Industry
- DEVS
- APLM Blank Checks
- Sector
- DEVS
- APLM Finance
- Exchange
- DEVS NYSE
- APLM Nasdaq
- Market Cap
- DEVS 16.5M
- APLM 15.6M
- IPO Year
- DEVS N/A
- APLM N/A
- Fundamental
- Price
- DEVS $0.78
- APLM $9.75
- Analyst Decision
- DEVS
- APLM Strong Buy
- Analyst Count
- DEVS 0
- APLM 2
- Target Price
- DEVS N/A
- APLM $425.00
- AVG Volume (30 Days)
- DEVS 9.6M
- APLM 107.4K
- Earning Date
- DEVS 02-12-2025
- APLM 02-15-2025
- Dividend Yield
- DEVS N/A
- APLM N/A
- EPS Growth
- DEVS N/A
- APLM N/A
- EPS
- DEVS N/A
- APLM N/A
- Revenue
- DEVS N/A
- APLM $2,101,000.00
- Revenue This Year
- DEVS N/A
- APLM N/A
- Revenue Next Year
- DEVS N/A
- APLM N/A
- P/E Ratio
- DEVS N/A
- APLM N/A
- Revenue Growth
- DEVS N/A
- APLM 70.54
- 52 Week Low
- DEVS $0.48
- APLM $6.50
- 52 Week High
- DEVS $1.91
- APLM $105.00
- Technical
- Relative Strength Index (RSI)
- DEVS N/A
- APLM 50.39
- Support Level
- DEVS N/A
- APLM $7.23
- Resistance Level
- DEVS N/A
- APLM $8.88
- Average True Range (ATR)
- DEVS 0.00
- APLM 1.37
- MACD
- DEVS 0.00
- APLM 0.21
- Stochastic Oscillator
- DEVS 0.00
- APLM 57.91
About DEVS DEVVSTREAM CORP
DevvStream Corp is a technology based ESG company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. It works with governments and corporations to achieve their sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.